09:29 AM EDT, 08/21/2025 (MT Newswires) -- AbbVie ( ABBV ) said Thursday that topline results from the second of two pivotal studies of a phase 3 trial showed that upadacitinib improved scalp and non-scalp hair regrowth in adult and adolescent patients with severe alopecia areata.

The study achieved the primary endpoint with 45.2% and 55% of patients treated with 15 mg or 30 mg doses, respectively, reaching at least 80% scalp hair coverage at week 24, compared with 1.5% of patients receiving placebo, the company said

AbbVie ( ABBV ) said the study also met key secondary endpoints, including improvements in eyebrows and eyelashes.

The safety profile of both doses was generally consistent with that in approved indications, the company said.